Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment

Non-small cell lung cancer (NSCLC) patients are often elderly or unfit and thus cannot tolerate standard aggressive therapy regimes. In our study, we test the efficacy of the DNA-hypomethylating agent decitabine (DAC) in combination with all-trans retinoic acid (ATRA), which has been shown to posses...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of cancer 2024-03, Vol.154 (6), p.1029-1042
Hauptverfasser:	Pelos, Giulia, Riester, Marisa, Pal, Jagriti, Myacheva, Ksenia, Moneke, Isabelle, Rotondo, John Charles, Lübbert, Michael, Diederichs, Sven
Format:	Artikel
Sprache:	eng
Schlagworte:	5-aza-2'-deoxycytidine Aged Cancer Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - metabolism Cell Line, Tumor Cell Proliferation Cell viability Decitabine - pharmacology Decitabine - therapeutic use Drug resistance Gene expression Humans K-Ras protein Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - genetics Lung Neoplasms - metabolism Medical research Non-small cell lung carcinoma Older people Proteomics Proto-Oncogene Proteins p21(ras) - genetics Proto-Oncogene Proteins p21(ras) - metabolism Retinoic acid Senescence Side effects Small cell lung carcinoma Transcriptomics Tretinoin - pharmacology Tretinoin - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!